Company profile: Veraxa Biotech
1.1 - Company Overview
Company description
- Provider of ADC development solutions, combining targeted antibody discovery and bioconjugation. Offerings include droplet-based microfluidics for functional antibody screening, site-specific conjugation via proprietary bioorthogonal click chemistry to create uniform, stable ADCs, Positional Intelligence genetic code expansion for precise payload placement, and charged payloads to enhance manufacturing, efficacy, pharmacokinetics, and safety.
Products and services
- ADC Technology: Custom-engineered technology that architects precise positioning of conjugation sites on antibodies using click chemistry to create uniform, stable antibody-drug conjugates
- Functional Antibody Screening: High-throughput droplet-based microfluidics platform combining single-cell analysis with sorting to identify functional antibodies against a broad spectrum of targets
- Bioorthogonal Click Chemistry: Industrial-grade proprietary method enabling efficient, stable conjugation of payloads to antibodies, improving ADC homogeneity and stability
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Veraxa Biotech
Paradigm
HQ: United States
Website
- Description: Provider of cutting-edge molecular diagnostics and biomarker-driven clinical trials for cancer patients and industry, using Next-Gen Sequencing and other biomarker analysis to deliver information on the genomic and proteomic landscape of a patient's cancer and potential therapies based on specific characterization of the cancer.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Paradigm company profile →
Mustang Bio
HQ: United States
Website
- Description: Provider of clinical-stage biopharmaceutical therapies for B-cell Non-Hodgkin Lymphoma, X-linked severe combined immunodeficiency (XSCID), and glioblastoma. Pipeline includes MB-106 (third-generation fully human antibody); MB-107/MB-207 (safety-modified lentiviral gene therapies for XSCID); MB-101 (IL13Rα2-targeted CAR T); MB-108 (oncolytic herpes simplex virus); and MB-109 (combining CAR T with oHSV to improve efficacy).
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Mustang Bio company profile →
MabVax Therapeutics
HQ: United States
Website
- Description: Provider of proprietary anti-cancer immunotherapies as a biopharmaceutical company focused on their commercialization.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full MabVax Therapeutics company profile →
Point Biopharma
HQ: United States
Website
- Description: Provider of radioligand therapies for cancer, with a globally focused platform for the clinical development and commercialization of radioligands. Combines a portfolio of radiopharmaceutical assets with a seasoned management team and expertise in radioisotopes.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Point Biopharma company profile →
GeminX Pharmaceuticals
HQ: Canada
Website
- Description: Provider of novel, targeted cancer therapeutics, dedicated to the discovery, development and commercialization of treatments based on research on the Bcl-2 cell death regulation pathway, including the discovery of GX15-070 (obatoclax), a novel small molecule.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full GeminX Pharmaceuticals company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Veraxa Biotech
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Veraxa Biotech
2.2 - Growth funds investing in similar companies to Veraxa Biotech
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Veraxa Biotech
4.2 - Public trading comparable groups for Veraxa Biotech
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →